Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s What Happened

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $17.89, but opened at $18.4350. Daiichi Sankyo shares last traded at $18.2075, with a volume of 8,958 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce”.

Daiichi Sankyo Trading Up 1.8%

The business has a fifty day moving average price of $16.95 and a 200-day moving average price of $17.37. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18. The company has a market cap of $33.93 billion, a P/E ratio of 21.18, a PEG ratio of 3.24 and a beta of -0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.22% and a net margin of 10.92%.The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.